Allergic bronchopulmonary aspergillosis in resistant asthmatics

Background: Allergic bronchopulmonary aspergillosis (ABPA) is an immune mediated lung disease caused due to hypersensitivity reaction of antigen Aspergillus fumigates. ABPA more prevalent in patients with asthma and cystic fibrosis. Thus, the current investigation was done estimate prevalence association resistant asthma, identify clinical laboratory pointers effect its treatment on course asthma.Methods: Current a prospective non-blinded study conducted Rajiv Gandhi government general hospital, Chennai bronchial having frequent exacerbation related problems. Demographic, (hematological) radiological investigations were performed for staging all enrolled patients. Follow up periodically investigate re-admission respiratory events or other illnesses. All collected data statistically analyzed.Results: Prevalence 19%. Positive family history, history atopy recurrent exacerbations identified as significant risk factors among Whereas duration severity had no patients, bronchiectasis parenchymal damage significantly observed ABPA. Skin prick test serum eosinophils IgE antibody levels good screening parameters Prednisolone itraconazole are considered highly reliable effective strategies ABPA.Conclusions: revealed that must be possible prevailing refractory cases conventional steroids.